# Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment

> **NCT06199232** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Peking University** · enrollment: 47 (estimated)

## Conditions studied

- Liver Metastasis Colon Cancer
- ctDNA Genotype
- MSS
- Failed From Standard Treatment

## Interventions

- **DRUG:** HAIC+targeted therapy+PD-1 inhibitor

## Key facts

- **NCT ID:** NCT06199232
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-23
- **Primary completion:** 2026-05-23
- **Final completion:** 2027-05-23
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06199232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06199232, "Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06199232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*